PMID- 37141388
OWN - NLM
STAT- MEDLINE
DCOM- 20231005
LR  - 20231006
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 228
IP  - 7
DP  - 2023 Oct 3
TI  - Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 
      Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older 
      Adults.
PG  - 868-877
LID - 10.1093/infdis/jiad133 [doi]
AB  - BACKGROUND: Intradermal (ID) vaccination may alleviate COVID-19 vaccine shortages 
      and vaccine hesitancy. METHODS: Persons aged >/=65 years who were vaccinated with 
      2-dose ChAdOx1 12-24 weeks earlier were randomized to receive a booster 
      vaccination by either ID (20 microg mRNA-1273 or 10 microg BNT162b2) or intramuscular 
      (IM) (100 microg mRNA-1273 or 30 microg BNT162b2) route. Anti-receptor-binding domain 
      (RBD) immunoglobulin G (IgG), neutralizing antibody (NAb), and interferon gamma 
      (IFN-gamma)-producing cells were measured at 2-4 weeks following vaccination. 
      RESULTS: Of 210 participants enrolled, 70.5% were female and median age was 77.5 
      (interquartile range, 71-84) years. Following booster dose, both ID vaccinations 
      induced 37% lower levels of anti-RBD IgG compared with IM vaccination of the same 
      vaccine. NAb titers against ancestral and Omicron BA.1 were highest following IM 
      mRNA-1273 (geometric mean, 1718 and 617), followed by ID mRNA-1273 (1212 and 
      318), IM BNT162b2 (713 and 230), and ID BNT162b2 (587 and 148), respectively. 
      Spike-specific IFN-gamma responses were similar or higher in the ID groups compared 
      with IM groups. ID route tended to have fewer systemic adverse events (AEs), 
      although more local AEs were reported in the ID mRNA-1273 group. CONCLUSIONS: 
      Fractional ID vaccination induced lower humoral but comparable cellular immunity 
      compared to IM and may be an alternative for older people. CLINICAL TRIALS 
      REGISTRATION: TCTR20220112002.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Assantachai, Prasert
AU  - Assantachai P
AD  - Department of Preventive and Social Medicine.
FAU - Niyomnaitham, Suvimol
AU  - Niyomnaitham S
AD  - Department of Pharmacology.
AD  - Siriraj Institute of Clinical Research.
FAU - Chatthanawaree, Wichai
AU  - Chatthanawaree W
AD  - Department of Preventive and Social Medicine.
FAU - Intalapaporn, Somboon
AU  - Intalapaporn S
AD  - Department of Preventive and Social Medicine.
FAU - Muangpaisan, Weerasak
AU  - Muangpaisan W
AD  - Department of Preventive and Social Medicine.
FAU - Phannarus, Harisd
AU  - Phannarus H
AD  - Department of Preventive and Social Medicine.
FAU - Saichompoo, Rangsimatiti Binda
AU  - Saichompoo RB
AD  - Siriraj Institute of Clinical Research.
FAU - Sura-Amonrattana, Unchana
AU  - Sura-Amonrattana U
AD  - Department of Medicine.
FAU - Wongprompitak, Patimaporn
AU  - Wongprompitak P
AD  - Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Toh, Zheng Quan
AU  - Toh ZQ
AD  - Infection and Immunity, Murdoch Children's Research Institute.
AD  - Department of Pediatrics, University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Licciardi, Paul V
AU  - Licciardi PV
AD  - Infection and Immunity, Murdoch Children's Research Institute.
AD  - Department of Pediatrics, University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Srisutthisamphan, Kanjana
AU  - Srisutthisamphan K
AD  - National Center for Genetic Engineering and Biotechnology, National Science 
      Development Agency, Pathum-thani.
FAU - Chokephaibulkit, Kulkanya
AU  - Chokephaibulkit K
AUID- ORCID: 0000-0002-0140-4600
AD  - Siriraj Institute of Clinical Research.
AD  - Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
LA  - eng
SI  - TCTR/TCTR20220112002
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (BNT162 Vaccine)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - COVID-19 vaccine booster shot
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - 2019-nCoV Vaccine mRNA-1273
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral
MH  - BNT162 Vaccine
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/immunology
MH  - *Immunogenicity, Vaccine
MH  - Immunoglobulin G
MH  - Southeast Asian People
MH  - Vaccination
MH  - Aged, 80 and over
PMC - PMC10547455
OTO - NOTNLM
OT  - COVID-19 booster vaccination
OT  - immune responses
OT  - intradermal
OT  - mRNA vaccines
OT  - older adults
COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. 
      All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts 
      of Interest. Conflicts that the editors consider relevant to the content of the 
      manuscript have been disclosed.
EDAT- 2023/05/04 18:42
MHDA- 2023/10/05 06:43
PMCR- 2023/05/04
CRDT- 2023/05/04 14:13
PHST- 2022/12/26 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/10/05 06:43 [medline]
PHST- 2023/05/04 18:42 [pubmed]
PHST- 2023/05/04 14:13 [entrez]
PHST- 2023/05/04 00:00 [pmc-release]
AID - 7152394 [pii]
AID - jiad133 [pii]
AID - 10.1093/infdis/jiad133 [doi]
PST - ppublish
SO  - J Infect Dis. 2023 Oct 3;228(7):868-877. doi: 10.1093/infdis/jiad133.